Carlos Castaneda ~ The Warriors Path / Concepts In Shamanism

VETERANS AGAINST TREASON CHAT GPT ON THE CURRENT USE OF VARIOUS BRANDS OF SYNTHETIC SQUALENE ADJUVANTS.

Section # 1.) MF59
AS03 is an oil-in-water emulsion adjuvant developed by GlaxoSmithKline (GSK), designed to enhance the immune response in vaccines. It contains squalene, DL-α-tocopherol (vitamin E), and polysorbate 80.

Here’s a list of vaccines that use the AS03 adjuvant:
⸻
Licensed / Widely Used Vaccines
1. Pandemrix
• Purpose: H1N1 influenza (swine flu)
• Developer: GSK
• Use: Used during the 2009 H1N1 pandemic in Europe.
2. Arepanrix
• Purpose: H1N1 influenza
• Developer: GSK
• Use: Used in Canada during the 2009 H1N1 pandemic.
3. Qpan H5N1 (Prepandrix successor)
• Purpose: Avian influenza (H5N1)
• Developer: GSK
• Use: Approved as a prepandemic vaccine by the FDA in 2023.
4. Shingrix (Early versions during development)
• Note: Some early formulations of Shingrix used AS03 during trials, though the final licensed version uses AS01B instead.

⸻bu
COVID-19 Vaccines (Investigational / Emergency Use)
5. Covaxin (Bharat Biotech + GSK collaboration version)
• Purpose: COVID-19
• Note: A version of Covaxin was developed with AS03 for broader immune response, particularly in global alliances like COVAX.
6. Sanofi–GSK COVID-19 vaccine (Vidprevtyn Beta)
• Purpose: COVID-19
• Developer: Sanofi/GSK
• Adjuvant: AS03
• Use: Received marketing authorization in the EU.

⸻

Experimental / Clinical Trial Vaccines
7. GSK’s RSV vaccines (older candidates)
• Purpose: Respiratory Syncytial Virus
• Note: Some candidates used AS03 before final versions moved to other adjuvants.
8. H7N9 Influenza vaccines (clinical trials)
• Purpose: Avian influenza (H7N9)
• Adjuvant: AS03 used in several trials for prepandemic preparedness.
//……
////////…/……….:.:

Section # 2.) AS03

AS03 is an oil-in-water emulsion adjuvant developed by GlaxoSmithKline (GSK), designed to enhance the immune response in vaccines. It contains squalene, DL-α-tocopherol (vitamin E), and polysorbate 80.

Here’s a list of vaccines that use the AS03 adjuvant:

⸻

Licensed / Widely Used Vaccines
1. Pandemrix
• Purpose: H1N1 influenza (swine flu)
• Developer: GSK
• Use: Used during the 2009 H1N1 pandemic in Europe.
2. Arepanrix
• Purpose: H1N1 influenza
• Developer: GSK
• Use: Used in Canada during the 2009 H1N1 pandemic.
3. Qpan H5N1 (Prepandrix successor)
• Purpose: Avian influenza (H5N1)
• Developer: GSK
• Use: Approved as a prepandemic vaccine by the FDA in 2023.
4. Shingrix (Early versions during development)
• Note: Some early formulations of Shingrix used AS03 during trials, though the final licensed version uses AS01B instead.

⸻

COVID-19 Vaccines (Investigational / Emergency Use)
5. Covaxin (Bharat Biotech + GSK collaboration version)
• Purpose: COVID-19
• Note: A version of Covaxin was developed with AS03 for broader immune response, particularly in global alliances like COVAX.
6. Sanofi–GSK COVID-19 vaccine (Vidprevtyn Beta)
• Purpose: COVID-19
• Developer: Sanofi/GSK
• Adjuvant: AS03
• Use: Received marketing authorization in the EU.

⸻

Experimental / Clinical Trial Vaccines
7. GSK’s RSV vaccines (older candidates)
• Purpose: Respiratory Syncytial Virus
• Note: Some candidates used AS03 before final versions moved to other adjuvants.
8. H7N9 Influenza vaccines (clinical trials)
• Purpose: Avian influenza (H7N9)
• Adjuvant: AS03 used in several trials for prepandemic preparedness.

\\…………………..

Section # 3.) AF04

AF04 is an experimental vaccine adjuvant composed of the synthetic toll-like receptor 4 (TLR4) agonist E6020 formulated within AF03, a thermoreversible squalene emulsion. This combination has demonstrated synergistic enhancement of both antibody and Th1 cellular immune responses in preclinical studies involving model antigens such as Chlamydia trachomatis major outer membrane protein (Ct-MOMP) and human cytomegalovirus glycoprotein B (CMV-gB) .

Currently, AF04 is not included in any licensed human vaccines. Its application has been limited to preclinical research settings, and there is no evidence of its use in approved vaccines for human or veterinary medicine.